Australia has closed a deal for 300,000 courses of an antiviral pill showing promising signs of slashing COVID-19 deaths and hospitalisations.
Molnupiravir is still being trialled in the US and is yet to gain regulatory authorisation.
Australia has closed a deal for 300,000 courses of an antiviral pill showing promising signs of slashing COVID-19 deaths and hospitalisations.
Molnupiravir is still being trialled in the US and is yet to gain regulatory authorisation.